June 19, 2006—Researchers fear a promising new class of drugs that block HIV’s ability to enter cells through the CCR5 receptor could be highly toxic and in some cases cause more rapid disease progression. Two pharma companies are currently developing CCR5 drugs and Pfizer may file its version for FDA approval this year.